Introducing the Antibody R&D Module to Patsnap Bio

The Antibody R&D module in Patsnap Bio connects antibody sequences with targets, binding units, experimental evidence, and source information to support antibody discovery and R&D.

Explore antibodies at both the whole-antibody and individual binding-unit level, helping you investigate complex antibody formats, compare candidates, and connect sequence information with experimental and patent evidence.

What's new in the Antibody R&D module?

The Antibody R&D module has undergone a major upgrade focused on more than the user interface. The update expands the underlying antibody data, restructures how antibody information is organized, and introduces new search, analysis, and connectivity capabilities for antibody R&D workflows.

• Antibody records are enriched with additional R&D data, including in vitro and in vivo bioactivity, germline annotations, Fc mutations, isoelectric point (pI), net charge, and PK data where available.

  This brings sequence, activity, and early developability-related data together to support candidate research and comparison.

• The underlying data structure has been reorganized around both the complete antibody and its individual binding units.

  This provides a clearer representation of antibody formats such as monoclonal, bispecific, multispecific, and heavy-chain-only antibodies. For complex antibodies, individual binding units can be connected with their corresponding VH/VL sequences, targets, and available activity data.

• Search using antigen or target, drug, antibody, patent, sequence code, or keyword, then refine the results using antibody-, binding-unit-, sequence-, activity-, drug-, and patent-related filters.

  This makes it easier to move from broad antibody discovery to a more focused set of candidates.

• Expanded sequence annotations provide additional context for antibody comparison, including VH and VL germlines, CDRs, Fc mutations, pI, net charge, and other sequence-derived information.

  Supported antibody numbering schemes and VH/VL comparison help users investigate sequence differences and mutation sites across candidates.

• Integration with Patsnap Synapse connects antibody R&D information with associated drug and development context.

  Where available, users can explore associated drugs, direct sequences, development phase, and clinical trial information to add asset and clinical context to antibody research.

• Antibody Collection provides a dedicated environment for comparing selected antibodies and binding units side by side.

  Users can compare germlines, VH/VL sequences, mutations, sequence length, pI, net charge, and available activity data such as KD, EC50, and IC50 to investigate differences between candidates.

Who can the Antibody R&D module help?

The Antibody R&D module is designed to support teams working across target discovery, antibody discovery, and computational biology, including researchers developing antibodies, synthetic biology approaches, cell therapies, ligands, and proteins, as well as CROs.

It can help teams investigate questions such as:

• Which binders warrant further review?
• Which hits merit deeper investigation?
• What engineering changes have previously been disclosed?

Antibody R&D brings activity and binding data together with sequence and antibody information to support candidate comparison, including germline, Fc mutations, pI, and other available data points.

What can you use Antibody R&D for?

• Search by antigen or target, drug, antibody, patent, sequence code, or keyword to identify relevant antibodies and explore their associated sequence, activity, and patent evidence.

• Compare complete antibodies and individual binding units using sequence annotations, experimental activity, and early developability-related information such as germline, pI, net charge, and Fc mutations.

• Compare VH and VL sequences, germlines, CDRs, and mutations alongside available affinity and activity data to investigate relationships between sequence variation and experimental activity.

• Trace antibodies and sequences to source patents, continue sequence investigation in Bio Sequence Search, and explore associated drug development information from Patsnap Synapse.

How can I connect Antibody R&D with other Patsnap products?

Antibody R&D can be used as part of a connected workflow across R&D, IP, and competitive intelligence. Start by reviewing antibody evidence in Antibody R&D, then continue into other Patsnap products when you need deeper patent, sequence, or drug development context.

• Use Antibody R&D to identify relevant antibodies, binding units, and supporting patent evidence. From the Patents view, connect to Patsnap Analytics when you need to continue with patent-centric searching and review.

• Antibody R&D helps you understand what has been disclosed and tested by bringing together whole antibodies, binding units, sequence annotations, and reported evidence.

  When you need to investigate where a sequence or similar sequence appears, continue with antibody sequences or CDRs in Bio Sequence Search. This supports sequence similarity, novelty, patent exposure, and FTO investigation.

• Connect antibody and antigen evidence with Patsnap Synapse to investigate associated drugs and their development context.

  Where available, you can explore direct sequences, development phase, pipeline information, and clinical trial evidence to understand how an antibody or target relates to the broader therapeutic landscape.

Together, these connections support a workflow from comparing antibody evidence, to checking sequence novelty and patent exposure, to adding pipeline and clinical trial context.

What data is available?

The Antibody R&D dataset brings together antibody information from patents, NCBI, PDB, UniProt, literature, and Patsnap Synapse.

Available data dimensions include:

• Antibodies and binding units: Whole-antibody and individual binding-unit records, including complex antibody formats.
• Antigens and targets: Antigens associated with antibodies and binding units, including standardized target information where available.
• Sequences and annotations: VH and VL sequences, CDRs, germlines, Fc mutations, pI, net charge, and other available sequence annotations.
• Binding and activity data: KD, EC50, IC50, and other available assay information.
• Experimental evidence: In vitro, in vivo, and PK data where available.
• Patent information: Source patents and related evidence supporting antibody records.
• Drug and development information: Associated drug information from Patsnap Synapse, including development and clinical context where available.

The Antibody R&D homepage provides an up-to-date snapshot of key dataset metrics, including unique antibodies, binding units, unique targets, and bioactivity records.

Select View Full Dashboard from the Antibody R&D homepage to explore the latest dataset coverage and additional information, including data growth, antibody sources, bioactivity records, experimental evidence, CDR3 diversity, and germline distribution. You can also view it here: Antibody R&D Dashboard.

Get started with Antibody R&D

To learn how to search, refine results, review antibodies and binding units, and compare selected candidates, see Bio Antibody R&D Module: How to use.

Key Takeaways

• Antibody R&D connects antibody sequences, binding units, targets, experimental evidence, and source information.
• Explore complete antibodies or individual binding units for discovery, candidate comparison, sequence analysis, and patent or drug investigation.
• Use the Antibody R&D dashboard to explore the latest dataset coverage and statistics.